BioInvent buys Merck single-use tech to up mAb capacity
BioInvent International AB has acquired a range of different single-use bioreactors from Germany’s Merck to up monoclonal antibody (mAb) capacity at its plant in Lund, Sweden.
The deal – financial terms of which were not provided – will see BioInvent install 3-, 50-, 200- and 1000-liter bioreactors from Merck’s Mobius range at the plant, with the idea being the range of sizes will simplify production scale-up.
Kristoffer Rudenholm Hansson, vice president of Technical Operations at BioInvent, said: “Merck’s single-use bioreactors most effectively addressed our current and future needs with a fully scalable system.”
BioInvent outlined its plan to increased mAb production capacity last September, citing the expansion of a customer contract as the driver.
At the time, the firm told us it used 500L Wave systems provided by GE Healthcare, but intended to install a 1,000L Single Use bioreactor (SUB).
